Stocks/NRC

NRC

National Research Corporation
Healthcare·Medical - Healthcare Information Services
$19.53
$440M market cap
Claude Rating
4/10UNDERWEIGHT
Revenue
$138.6M
Free Cash Flow
$17.4M
Rev Growth
+3.7%
FCF Margin
12.6%
P/FCF
25.3x
EV/FCF
29.6x
Fwd EV/EBITDA
12.9x
Fair Value
$15.50
Upside
-20.6%

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, an

2-Year Price History

$19.08-21.9%
$12$14$16$18$20$22$24volJun 24Oct 24Jan 25May 25Sep 25Jan 26May 26

Quarterly Financials & Projections

Quarterly Waterfall ($ M)
PeriodRevEBITDAOpInNIOCFFCFCapExCashDebtSharesROICIntCovEV/EBITDA
Est2027-Q438.311.9--6.1--5.8-2.342.0----------
Est2027-Q337.811.5--5.9--6.1-2.336.2----------
Est2027-Q237.311.2--5.6--4.7-2.430.2----------
Est2027-Q136.810.9--5.3--4.8-2.425.5----------
Est2026-Q436.410.6--5.1--5.1-2.420.7----------
Est2026-Q335.810.2--4.8--5.4-2.515.6----------
Est2026-Q235.39.9--4.6--3.5-2.510.3----------
Est2026-Q134.89.4--4.4--4.2-2.66.7----------
Act2026-Q134.87.75.63.27.25.4-1.82.678.021.922.6%6.2x16.0x
Act2025-Q435.26.84.71.87.26.1-1.14.179.021.816.2%5.0x11.8x
Act2025-Q334.69.97.74.113.810.2-3.62.280.022.627.9%6.8x13.3x
Act2025-Q234.03.41.6-0.1-1.1-4.2-3.05.381.022.75.1%3.3x11.1x
Act2025-Q133.610.28.65.86.73.7-3.02.565.223.040.9%11.3x11.5x
Act2024-Q436.911.19.66.66.41.9-4.44.264.423.445.2%15.3x14.1x
Act2024-Q335.89.68.05.79.47.8-1.63.553.623.847.5%13.5x13.8x
Act2024-Q235.010.48.96.26.81.5-5.30.542.223.959.1%18.7x22.0x
Act2024-Q135.310.28.86.412.07.9-4.11.742.124.065.8%16.9x22.6x
Act2023-Q438.013.211.78.911.77.9-3.86.739.624.692.0%49.1x23.9x
Act2023-Q338.011.810.07.99.85.4-4.53.823.824.7124.5%73.5x24.7x
Act2023-Q236.211.29.47.38.84.5-4.322.520.024.769.5%58.1x24.1x
Act2023-Q136.510.79.07.07.84.6-3.223.721.124.770.2%44.2x20.4x
Act2022-Q438.111.112.26.68.16.1-2.025.023.424.895.0%38.9x20.3x
Act2022-Q337.712.411.18.310.16.1-4.028.423.324.996.7%43.2x--
Act2022-Q237.312.711.58.39.88.5-1.333.024.425.293.0%39.9x--
Act2022-Q138.413.111.78.58.35.8-2.547.325.525.467.8%41.2x--
Historical Valuation

Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.

YearPriceRev GrEBITDA %EBITDAEV/EBITDAEV/FCFP/EP/S
202234.1932.5%4920.3×37.8×31.5×6.6×
202337.50-2.0%31.4%4723.9×49.9×35.0×7.3×
202417.06-3.7%28.8%4114.1×30.3×21.0×3.6×
202518.77-4.0%22.0%3011.8×22.8×24.4×2.1×
TTM19.53-1.9%20.1%280.0×0.0×0.0×0.0×
2026E19.53+2.6%0.3%00.0×0.0×0.0×0.0×
2027E19.53+5.5%0.3%00.0×0.0×0.0×0.0×

EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.

AI Analysis

LLM Evaluations

Claude4/10UNDERWEIGHTFV: $15.50

NRC Health is a niche healthcare analytics provider with a highly recurring (99%) revenue model and deep penetration into major US health systems. The TRCV recovery to $144.1M (+8% YoY) and improved sales productivity are genuine positives that should translate to modest revenue growth in 2026. However, the investment case is significantly weakened by: (1) a heavily leveraged balance sheet with debt/equity of 5.36x and thin liquidity, (2) compressed margins that may not fully recover given competitive pressures from Press Ganey and Qualtrics, (3) an unsustainable 128% dividend payout ratio, (4) concerning one-time items ($6.6M CEO signing bonus) that obscure true earnings power, and (5) a valuation at 25x P/FCF and 30x EV/FCF that prices in a recovery that is far from certain. The stock's ~4% decline in revenue and ~36% decline in operating income in FY2025 signal a business under real stress, not just a temporary blip. At current prices around $18/share, the risk/reward skews negative given the execution risk and balance sheet constraints.

Catalyst Sustained TRCV growth converting to visible revenue acceleration in FY2026 Q2-Q3, combined with margin normalization as one-time costs (CEO bonus, HQ renovation) roll off, could restore investor confidence. A strategic acquisition funded appropriately could also expand TAM.
Risk The overleveraged balance sheet (debt/equity 5.36x, current ratio 0.55) combined with an unsustainable dividend payout ratio creates a liquidity trap — if the revenue recovery stalls or a major customer churns, the company may face a balance sheet restructuring or forced dividend cut that would crater the stock.
Trend
IMPROVING
Mgmt
6/10
Quarter
5/10
Exp. Move
-3.0%

Latest Earnings Call

Transcript Summary

NRC Health reported Q4 2025 revenue of $35.2 million and a Total Recurring Contract Value (TRCV) of $144.1 million, an 8% year-over-year increase. Despite a 4% decline in full-year revenue attributed to 2024 attrition, management expressed high confidence for 2026, citing five consecutive quarters of sequential TRCV growth. A major sales reorganization drove an 86% increase in new sales, while gross dollar retention reached a seven-year high. NRC Health’s product portfolio is centered on four pillars: Experience, Enablement, Strategic Insights, and Governance. The Enablement segment, specifically the Rounding solution, nearly doubled its TRCV in 2025. The company is also integrating AI to enhance sentiment analysis and frontline feedback. Financially, NRC Health maintains a strong 29% adjusted EBITDA margin and a 99% recurring revenue model. Capital allocation remains balanced between reinvestment, a $0.12 quarterly dividend, and strategic M&A. Management highlighted that serving 74% of the top 100 health systems provides a stable foundation for expansion. Key growth catalysts for 2026 include the scaled sales model, increased cross-selling, and continued product innovation to turn patient insights into measurable operational improvements for healthcare providers.

Valuation & Metrics

Market Stats

Price$19.53
Market Cap$440M
Enterprise Value$516M
P/S Ratio3.2x
P/FCF25.3x
EV/FCF29.6x
FCF Margin (TTM)12.6%
FCF Yield4.0%
Dividend Yield (TTM)3.7%
Annual Dilution-4.6%
CurrencyUSD

TTM Financial Snapshot

Revenue$138.6M
Net Income$9.0M
Free Cash Flow$17.4M

Revenue Growth (YoY)+3.7%
EBITDA Margin20.1%
Net Margin6.5%
FCF Margin12.6%
CapEx % of Revenue6.9%
SBC % of Revenue3.4%
ROIC18.0%
WC Change % Rev2.5%
Interest Coverage5.4x

DCF Fair Value Estimate

$7.36
-62.3% upside
Fair Enterprise Value$237M
− Net Debt$75M
= Fair Equity$161M
Revenue Growth5.6% → 3.0%
FCF Margin12.6% → 15.0%
Discount Rate14.0%
Terminal EV/FCF14.0x

Forward Outlook & Risk

Short Interest

Short % of Float3.4%
Short Shares0.4M
Days to Cover5.5
Change (vs Prior)+4.2%
Short % Float History
3.40%+0.30pp
2.8%3.0%3.2%3.4%3.6%04-3007-1509-1511-1401-1504-30

Options

Call IV (ATM)36%
Put IV (ATM)41%
ATM Spread1.0%
Call $OI (near money)$16K
Put $OI (near money)$5K
ATM ExpiryJuly 17, 2026 (56D)
ATM Strike$20.0
Major Expirations2
Near-money chain · July 17, 2026
StrikeCall Bid/AskCall OIPut Bid/AskPut OI
$12.50$4.10/$9.000--/$2.550
$15.00$1.90/$6.700$0.15/$0.250
$17.50$1.80/$2.507$0.40/$0.850
$20.00$0.65/$0.851$1.35/$2.000
$22.50--/$0.250$3.10/$3.900
Snapshot: 2026-05-22

Forward Projections & Estimates

NTM Revenue Growth+2.6%
Forward FCF Margin12.8%
Forward EBITDA Margin28.1%
Forward P/FCF24.2x
Forward EV/FCF28.4x
Forward Int. Coverage7.7x
Model Risk Score6/10
Bankruptcy Odds8%
Est. Borrow Rate7.5%
Terminal EV/FCF14.0x
LT Growth3.0%
LT FCF Margin15.0%

Employees

Headcount368
Revenue / Employee$376,742
Gross Profit / Employee$210,410
2022: 491 → 2023: 435 → 2024: 368 → 2025: 357 (-10% CAGR)

Institutional Ownership

Headline & net flow

NET BUYING

In Q1 2026 so far (quarter still filing), institutions are net buyers — bought 5.5% of float, sold 2.8%.

Net flow · Q1 2026still filing
+2.7% of float (net)
Bought 5.5% · Sold 2.8%
119 filers reported (last quarter: 116)

Ownership composition

Active
29.6%(+6.6% YoY)
104 filers
hedge / family / endowment
Retail funds
Fidelity, Schwab, 401(k)
Passive
12.9%(+1.9% YoY)
10 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.1% YoY)
4 filers
Citadel, Susquehanna
Insiders
4.5%
Form 4 — latest per insider
0%25%50%75%100%2022-062023-032023-122024-092025-062026-03
ActiveRetail fundsPassiveMarket makersRetail direct

Top holders

Fund$ valueCost basisΔ QoQΔ YoYα lifeFund AUM
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC$44.8M$34.73−$365K−$6.6M-0.8%$34.05B
MORGAN STANLEY$17.0M$31.91−$31K+$2.5M-0.3%$1.65T
BlackRock, Inc.Passive$16.6M$21.50−$500K−$2.5M-0.2%$5.69T
VANGUARD CAPITAL MANAGEMENT LLCPassive$11.3M$16.98+$11.3M+$11.3M$4.04T
DIMENSIONAL FUND ADVISORS LPPassive$8.3M$37.02−$81K−$1.1M-0.4%$480.92B
GEODE CAPITAL MANAGEMENT, LLCPassive$6.7M$29.67+$176K−$896K+2.3%$1.61T
QV Investors Inc.$6.5M$34.20+$0+$458K-0.4%$1.24B
RENAISSANCE TECHNOLOGIES LLC$5.8M$22.83−$175K−$504K+1.2%$63.91B
STATE STREET CORPPassive$5.2M$33.30−$150K−$551K-0.2%$2.89T
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC$4.9M$18.83−$943K+$2.2M-0.1%$31.89B
NORTHERN TRUST CORPPassive$4.3M$27.15+$535K−$957K-0.2%$755.34B
Bank of New York Mellon Corp$4.3M$21.41+$165K+$705K-0.2%$543.21B
HEARTLAND ADVISORS INC$4.0M$17.36+$3.2M+$4.0M-0.4%$1.96B
Willis Investment Counsel$3.8M$18.90+$703K+$2.7M-1.4%$1.83B
iA Global Asset Management Inc.$3.2M$41.93+$0+$0-0.2%$7.05B
AQR CAPITAL MANAGEMENT LLC$2.9M$18.46−$763K+$1.1M-0.2%$218.19B
Northwest & Ethical Investments L.P.$2.2M$35.79+$0+$0-0.2%$4.31B
WELLS FARGO & COMPANY/MN$2.0M$33.42−$159K−$966K-0.2%$497.71B
BANK OF AMERICA CORP /DE/$1.9M$32.89+$56K−$54K-0.1%$1.36T
CHARLES SCHWAB INVESTMENT MANAGEMENT INC$1.9M$26.91−$44K−$121K+0.7%$645.81B
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.

Trading behavior

Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
-0.40%
avg per quarter
Holders (ex-self)
-0.39%
excl. this stock
Buyers (this Q)
-0.19%
30 buyers · $0.02B in
Sellers (this Q)
-0.33%
58 sellers · $0.02B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+5.7%
how holders react when this stock falls
On quiet Qs
+10.3%
−10% to +10% baseline
On rallies (+10%+)
-30.6%
how they react when this stock rises
Holders' portfolio flow this Q
+0.9%
inflows — adds are organic
Sellers' portfolio flow this Q
+3.7%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-2.7%
Holder mid (any stock)
-0.6%
Holder rally (any stock)
-2.8%

Top Holders Over Time

5-year share-count history (top 10 holders by peak, incl. exited) + price

01.6M3.3M4.9M6.6M$12$20$27$35$422021-062022-062023-062024-062025-062026-03
hover the chart for per-quarter detailprice (right axis)
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC2.6MNeuberger Berman Group LLCMORGAN STANLEY1.0MATLANTA CAPITAL MANAGEMENT CO L L CConestoga Capital Advisors, LLCRENAISSANCE TECHNOLOGIES LLC341KQV Investors Inc.381KAMERIPRISE FINANCIAL INC42KInvesco Ltd.21KTouchstone Capital, Inc.

Analyst Coverage

Analyst Coverage
Consensus Estimates
QuarterRevenueEBITDANet IncEPSEPS Range# Analysts
2022 Q133M23M16M$0.30$0.30 – $0.3010
2022 Q257M21M13M$0.46$0.37 – $0.5620
2022 Q371M12M6M$0.32$0.25 – $0.3918
2022 Q474M22M14M$0.48$0.39 – $0.5815
2023 Q168M26M18M$0.67$0.53 – $0.8015
2023 Q263M23M15M$0.51$0.41 – $0.6220
2023 Q379M14M7M$0.35$0.28 – $0.4312
2023 Q481M24M16M$0.53$0.43 – $0.6420
2024 Q175M28M19M$0.73$0.58 – $0.8814
2025 Q335M12M0M$0.00$0.00 – $0.007

Corporate

Executive Compensation (2023-2025)

Direct Pay$24.7M
Incentive & Other$6.6M
Total Compensation$31.2M
% of Revenue7.3%

Insider Trading (last 12mo)

Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$108K
2 txns · 2 insiders · 8,771 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
DateSideInsiderTitleSharesPriceDollarsOwned $
2026-02-17BUYHARRISON SHANE Rofficer: EVP & Chief Financial Officer8,000$12.27$98K$98K
2025-07-31BUYFreeman Jordan Nicoleofficer: Chief Accounting Officer771$12.97$10K$10K

Order Flow (FINRA, ~3w lag)

16.6%retail-0.5pp
29.4%dark+2.9pp
week of 2026-04-13
10%20%30%40%24-1125-0225-0525-0825-1126-0226-04retail (non-ATS)dark (ATS)
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.

Revenue Breakdown

Revenue Segments

By Geography (2024-Q4)
UNITED STATES$107.8M+184%

Filing Risk Analysis

Filing Risk Scores

NRC Health: Routine Compliance Filing Devoid of Forensic Red Flags

Overall Risk
3/10
Fraud
1/10
Dilution
2/10
Insolvency
2/10
Earnings Overstated
5/10
Hidden Liabilities
3/10
Legal
2/10
Audit Warnings
1/10
Hidden Upside
5/10
Contextually Acceptable
10/10

Counter-Thesis

Counter-Thesis & Recent News

📰 Recent News

NRC reported a challenging FY 2025 with revenue declining 4% YoY to $137.4 million and operating income plunging 36% to $22.6 million. Q4 2025 revenue specifically fell 5% to $35.2 million. In March 2026, Weiss Ratings downgraded the stock from 'Hold' to 'Sell' (d+), and technical analysis from April 2026 shows a sell signal from the short-term moving average following a 5.5% price drop on April 21. While the company authorized a $60 million share repurchase program in March 2026, the underlying financials remain under pressure. (Sources: StockTitan, MarketBeat, Investing.com)

🐻 Bear Case

The core bear case centers on deteriorating profitability and a potentially unsustainable capital return policy. Operating margins compressed from 25% to 16% in FY 2025, and net profit margins fell to 11.6%. Despite these headwinds, the company maintains a dividend that reflects a 128% payout ratio, which is not well-covered by current earnings or free cash flow. Furthermore, a high debt-to-equity ratio of 5.36 and thin liquidity (current ratio of 0.55) limit the company's financial flexibility in a high-interest-rate environment. (Sources: MarketBeat, Simply Wall St, StockTitan)

🚩 Red Flags

Heavy customer concentration is a major risk, with the 10 largest customers accounting for 20% of total revenue as of early 2026. Additionally, the company is seeing significant 'large one-off items' impacting financial results, such as a $6.6 million signing bonus for the new CEO and costs related to headquarter renovations, which have masked the true decline in core cash generation. (Sources: Simply Wall St, Seeking Alpha, StockTitan)

⚔️ Competitive Threats

NRC faces intense competition from larger, better-capitalized players like Press Ganey and Qualtrics, which may be able to outspend NRC on AI-driven product innovation. Smaller tech-focused firms and internal healthcare research departments also exert pricing pressure. There is a persistent risk that NRC’s legacy survey-based model is being viewed by some health systems as a 'melting ice cube' compared to modern, real-time analytics platforms. (Sources: Seeking Alpha, Zacks, Matrix BCG)

💬 Customer Sentiment

Customer sentiment is currently mixed; while the company reported a '7-year high' in gross dollar retention in early 2026, this follows a period of 'unusually heavy attrition' in late 2024 and 2025. The reliance on renewable contracts makes the business highly vulnerable to shifts in hospital operating budgets and management changes, with any perceived lag in innovation likely to drive further churn to more technologically advanced competitors. (Sources: MarketBeat, Zacks)

Full Earnings Call Transcript

Full Earnings Call Transcript — Q4 • 2026-02-03

Operator: Good afternoon. Thank you for attending today's NRC Fourth Quarter 2025 Results. My name is Victoria, and I'll be your moderator today. I would now like to pass the conference over to Jordan Freeman. Thank you. You may proceed Jordan.
Jordan Freeman: Welcome to NRC Health Earnings Conference Call for the Fourth Quarter ended December 31, 2025. I wanted to first let you know that we posted our earnings press release to the Investor Relations section on our website. On the call today, we have NRC Health's CEO, Trent Green and CFO, Shane Harrison. Before getting started, I'd like to emphasize that this call will include statements related to the expected future results of our company, which are, therefore, forward-looking statements. Our actual results may differ materially from our expectations due to a number of risks and uncertainties, including those described in our earnings release and other SEC filings. Today's remarks will also be references to non-GAAP financial measures. Additional information, including definitions and reconciliations between non-GAAP financial information and GAAP financial information is provided in the corresponding earnings press release, which is posted on NRC's Investor Relations website. A replay of this call will also be posted to the same website. With that, let me turn our call over to our CEO, Trent Green.
Trent Green: Good afternoon, everyone, and thank you for joining us for NRC Health's Fourth Quarter and Full Year 2025 Earnings Call. Today, we'll review our fourth quarter and full year results, highlight the progress we're seeing across the organization and outline our strategic priorities as we head into 2026. Starting with the fourth quarter. We delivered another strong period of execution, driven by deep engagement and alignment across our teams. Revenue for the quarter was $35 million, and adjusted EBITDA totaled $9 million. Importantly, total recurring contract value or TRCV, reached $144 million, up 8% year-over-year and marking our fifth consecutive quarter of sequential TRCV growth. With 99% of our revenue recurring, TRCV continues to be a reliable and predictable indicator of the revenue we expect to recognize over the next 12 months. This sustained momentum underscores the effectiveness of our go-to-market strategy and the strength of our value proposition as health care providers navigate an increasingly complex operating environment. Let me unpack what's driving this TRCV growth. At a high level, it reflects strong execution across our sales, customer success and product teams. First, our sales team reorganization and refined coverage model are clearly delivering results. Full year new sales increased 86% year-over-year, driven by a selling approach that more closely mirrors how health care systems are structured and how decisions are made. This realignment has enabled us to engage more effectively at multiple levels within customer organizations and drive larger, more strategic relationships. Second, our customer success teams have elevated the quality, depth and consistency of customer engagement. By strengthening relationships with key users and decision-makers we achieved the highest gross dollar retention rate we've seen in more than 7 years. Both new sales and retention have been further supported by continued investment in our product portfolio. Over the course of the year, we enhanced capabilities that directly address our customers' needs, whether that's enabling operational improvement through our enablement solutions or delivering deeper real-time insights that connect patient experience to health system outcomes. In addition to the focus we've placed on our sales, customer success and product teams, we've also been intentional about strengthening our leadership team to support the next phase of growth. In early January, we welcomed David Burik to lead our strategic insights and governance strategy. With more than 30 years of experience in health care consulting, David brings deep expertise in governance, system transformation and strategic decision-making. He has advised integrated delivery networks, managed care organizations, physician groups and hospitals through complex change and previously led Guidehouse Center for Healthcare Insights. His experience and thought leadership uniquely position him to accelerate growth and innovation across our Market Insights platform and the Governance Institute. David's addition is emblematic of our broader leadership build-out. Over the past years, we've intentionally recruited leaders who combine deep health care operations and solutions experience with strong subscription software and technology expertise. This blend is central to our strategy, pairing industry insight with the ability to scale technology-driven solutions so we can continue to deliver products that drive sustained results for our customers and the people they serve. As I mentioned on last quarter's call, our customer value proposition is built on 3 pillars: clear and actionable insights; deep partnership and engagement; and enablement tools that help health systems turn insight into action. With that framework in mind, I'd like to highlight what differentiates NRC Health and why this value proposition continues to resonate in the market. First, trust. We served 74% of the top 100 health systems in the country, and that scale is a direct result of the trust health care leaders place in our brand. We've reinforced our position as a secure, reliable and defensible partner through continued investment in data security and compliance, including our high trust certification. That trust is further reflected in our customer relationships with a Net Promoter Score of 68, driven by our differentiated customer success model. Second, expertise. NRC Health was built specifically for health care. For nearly 45 years, we've partnered with providers and helped define patient-centered care. Our solutions are grounded in deep health care operations knowledge and that expertise translates into solutions that leaders can effectively use to drive action in their organizations. Additionally, through the Governance Institute, we engage C-suite executives and boards with insights, best practices and peer connections that inform decision-making at the highest levels of health care organizations. And third, portfolio breadth, while market research and patient experience remain foundational, we built a broader and more powerful portfolio over time, now spanning 7 products across the following 4 solution categories. Our experience solutions, including patient experience, employee experience, reputation management and care transitions deliver actionable insights in how organizations serve and connect with patients and employees. Our enablement solutions help operationalize those insights by structuring and automating workflows and delivering personalized real-time guidance to frontline teams in the path of care. Our strategic insight solutions, which include our market insights and community insights products provide health care leaders with intelligence on their competitive landscape by providing rich data on consumer preferences, brand perception and care delivery expectations that is continuously updated via our surveying of over 300,000 consumers annually. And the fourth element of our portfolio, our governance solutions through the Governance Institute equip Boards and executive leadership teams with the frameworks, education and insights needed to strengthen organizational performance and long-term resilience. Together, these solutions create our differentiated insights, engagement, enablement flywheel. We capture insight into what patients, employees and communities expect and experience. We work with leaders to translate that insight into strategy, and we enable action through workflows, tools and best practices that deliver measurable, hard return on investment, creating a continuous cycle of improvement. Now let me return to what I see as our most compelling growth catalysts as we head into 2026. First, our go-to-market restructure is already showing up in our sales activity and results. As this model continues to scale, I expect it to be a meaningful tailwind through 2026. Second, we see continued opportunity to deepen adoption of our enablement solutions. Rounding represents our first major investment in this area. Just over a year ago, we acquired a workflow-driven solution designed to guide care teams toward high-value actions using both historical and real-time feedback, now fully integrated into our platform, Rounding has gained strong momentum with TRCV nearly doubling in 2025. Importantly, the opportunity extends well beyond Rounding. Health care systems are actively seeking solutions to drive measurable operational improvement across quality, safety, discharge planning and other critical functions. We believe enablement will be a meaningful and durable growth engine for NRC Health. Third, product innovation remains a strategic priority. We're investing in capabilities to deepen our differentiation, expand our addressable market and consistently deliver measurable ROI to our customers. AI is playing an increasingly important role in this work. We're using AI to drive greater depth and accuracy and sentiment analysis through comment summarization and our AI-enabled complement and service recovery capabilities. We've also announced a beta release of a new AI-powered listening capability within our Rounding solution, further enhancing the richness and timeliness of frontline feedback. Together, these innovations are helping our customers move faster from insight to action. Fourth, cross-sell remains a meaningful growth opportunity. as we deepen relationships across our customers' organizations, we see clear potential to expand adoption of enablement, strategic insights and governance solutions. Fifth, retention upside. Although, we experienced a 7-year high with retention rate, we see opportunity to strengthen our retention efforts as we harden the customer success initiatives we deployed in 2025. And finally, new logo growth. Our differentiated data assets and insights open the door to new buyers, new use cases and new markets beyond our historical footprint. As awareness of our broader platform continues to expand we believe this represents a meaningful and long-term growth opportunity for NRC Health. As I reflect on 2025, I'm proud of what our team has accomplished, driving strong TRCV growth, improving customer retention, strengthening our leadership team and maintaining disciplined expense management. The foundation is solid and the runway ahead is clear. The health care industry's need for what NRC Health delivers, turning Human Understanding into meaningful, measurable action has never been greater. Health care leaders are navigating unprecedented complexity, and they need partners they can trust, with the expertise to guide them and the technology to enable them. With that, let me turn it over to Shane to walk through our financial results.
Shane Harrison: Thank you, Trent. Today, I'll walk through our Q4 and full year 2025 results, then I'd like to touch on how our financial profile is distinctive as well as our strategy around capital allocation. Starting with the fourth quarter. Revenue was $35.2 million, down 5% year-over-year, but up 2% sequentially from Q3. The unusually heavy TRCV attrition we experienced in Q3 2024 continued to recognize revenue through Q4 of 2024, creating a difficult comparison for Q4 2025. Even against that headwind, our sequential revenue growth highlights the improving momentum in the business. TRCV reached $144.1 million, which was up 8% year-over-year and 2% sequentially. This was our fifth consecutive quarter of sequential TRCV growth and reflects the strong execution across our sales and customer success teams. Fourth quarter adjusted EBITDA was $8.7 million. As mentioned on the Q3 call, our Q4 operating expenses came in higher than the prior year due to the timing of our annual customer conference, the Human Understanding Beyond or HUB Conference, which we held in Q4 this year versus Q3 last year. Adjusted net income for the quarter was $3.4 million and adjusted EPS was $0.16 per share. Additionally, during the quarter, we paid a quarterly dividend of $0.12 per share, consistent with our commitment to returning capital to shareholders. Now turning to the full year picture. Revenue for 2025 was $137.4 million, down 4% from 2024. This decline was expected given our TRCV performance in 2024, where we saw elevated attrition in the second half of that year. However, with the TRCV growth of 8% in 2025, we are confident that revenue growth will follow in 2026. Adjusted EBITDA for full year 2025 was $40.2 million, representing a 29% margin. We held our margin profile even as revenue declined, underscoring our ability to fund the growth initiatives Trent outlined, while maintaining disciplined cost management. In other words, we're demonstrating that investing for growth and delivering strong profitability can go hand in hand. Adjusted net income for 2025 was $20.7 million and adjusted EPS was $0.93 per share. These results showcase our compelling financial profile. This profile includes our highly predictable revenue streams. With 99% of our revenue being recurring, we have a very good revenue visibility. And our TRCV metric has proven to be a very strong leading indicator of how our top line will perform. This predictability is rare and valuable. Our financial profile also boasts strong profit margins. Our adjusted EBITDA margin is currently near 30%, and we see upside as revenue recovers. As we execute on those 6 growth catalysts, we will ensure NRC is positioned well for margin expansion. Our free cash flow durability also adds to our unique financial profile. Our business converts earnings into free cash flow efficiently and our strong free cash flow margins allow us to fund growth investments and return capital to shareholders, which leads me to the final aspect of our financial profile, our thoughtful, impactful and diversified approach to capital allocation. We have a clear flexible framework for deploying capital. First, we're investing meaningfully in our business and technology, hiring talented people, innovating new capabilities and exploring Blue Water opportunities that can accelerate our growth and improve our competitive position. Second, we're returning capital to our shareholders. We do so directly through our dividend, which reflects our confidence in this financial profile as well as returning capital indirectly through the opportunistic share repurchases that offset dilution and enhance per share returns. Third, we are maintaining the flexibility to pursue highly strategic, accretive acquisitions that expand our addressable market, reinforce our competitive position and create incremental value by leveraging NRC's operating model to drive cost efficiencies, sales expansion and integration synergies. As we move into 2026, we look forward to driving growth, profitability and long-term value creation for our shareholders. The foundation is solid. The trajectory is clear, and I'm excited about the opportunity ahead. With that, I'll turn it back to Trent.
Trent Green: Thank you, Shane. I want to emphasize one key point. NRC Health is uniquely positioned to thrive in the evolving health care landscape. Our mission to turn Human Understanding into meaningful, measurable action resonates deeply with health care leaders, navigating unprecedented complexity. The momentum we've built in customer growth, retention, team building and financial execution gives me tremendous confidence in our ability to create lasting value. I'm grateful to our incredible team of associates, our loyal customers and our supportive investors for the trust you place in NRC Health. As a reminder, if you have questions or want to engage further, please contact us at the e-mail address ir@nrchealth.com.
Operator: That concludes today's call. Thank you for your participation, and have a wonderful rest of your day.